美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

三倍做多标普生物-Direxion

238.85

-4.2450-1.75%

成交量：18.99万

成交额：4,530.27万

市值：6.39亿

市盈率：- -

高：244.67

开：241.75

低：234.18

收：243.09

52周最高：341.93

52周最低：102.35

股本：267.45万

流通股本：267.45万

量比：1.09

换手率：7.10%

股息：0.90

股息率：0.38%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

集采围标案进入公诉阶段叠加FDA进口禁令，圣诺生物内外合规风险共振

@澜沧人 2027年度城乡居民基本医疗保险今天可以开始缴费啦！

异动解读｜三倍做多标普生物科技盘中上涨8.25%，生物科技板块杠杆ETF反弹

Alignment Healthcare股价跌至两年多以来的低点

每日经济新闻

Alignment Healthcare股价盘前下跌23.2%，此前美国医疗保险和医疗补助服务中心公布了2027年联邦医

医疗健康行业综述：市场观察

医疗保健综述：市场观察

鲁宾制药获得美国FDA批准，可推出植物甲萘醌注射乳剂。

医疗健康板块综述：市场观察

异动解读｜三倍做多标普生物科技盘中下跌8.24%，生物科技板块杠杆ETF承压明显

美国健康保险公司股走弱，Humana跌3.2%

每日经济新闻

乐普医疗(300003.SZ)子公司MWN117注射液获得美国FDA药物临床试验批准

普门科技(688389.SH)：H100Plus血红蛋白检测系统获得美国FDA 510(k)准入

普门科技：H100Plus血红蛋白检测系统获美国FDA准入

金达威(002626.SZ)子公司巴西甜蛋白产品获得美国FDA GRAS无异议函

乐普医疗：子公司MWN117获美国FDA批准开展I期临床

ST人福(600079.SH)子公司盐酸地尔硫䓬片获得美国FDA批准文号

金达威：巴西甜蛋白获美国FDA GRN 001305无异议函

ST人福：盐酸地尔硫䓬片获得美国FDA批准文号

医疗健康板块综述：市场观察

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/LABU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":238.845,"timestamp":1791818005876,"preClose":243.09,"halted":0,"volume":189901,"delay":0,"changeRate":-0.017462668147599673,"floatShares":2674486,"shares":2674486,"eps":0,"marketStatus":"交易中","change":-4.245,"latestTime":"10-12 11:13:51 EDT","open":241.75,"high":244.6716,"low":234.1841,"amount":45302716.09465,"amplitude":0.043142,"askPrice":239.54,"askSize":40,"bidPrice":238.41,"bidSize":240,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791835200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":243.09,"sharesOutstanding":3074486,"nav":242.822,"aum":649423578.22,"dividendRate":0.003766,"bidAskSpread":0.002692,"preHourTrading":{"tag":"盘前","latestPrice":242.43,"preClose":243.09,"latestTime":"09:29 EDT","volume":24862,"amount":6085203.2304,"timestamp":1791811795117,"change":-0.66,"changeRate":-0.002715,"amplitude":0.021844},"postHourTrading":{"tag":"盘后","latestPrice":242.18,"preClose":243.09,"latestTime":"19:59 EDT","volume":3944,"amount":956626.8862,"timestamp":1791590359878,"change":-0.91,"changeRate":-0.003743,"amplitude":0.004484},"volumeRatio":1.092179,"impliedVol":0.9614,"impliedVolPercentile":0.6773},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2674486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.092179,"shares":2674486,"dividePrice":0.8994,"high":244.6716,"amplitude":0.043142,"preClose":243.09,"low":234.1841,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":238.845,"committee":0.714286,"eps":0,"divideRate":0.003766,"volume":189901,"delay":0,"ttmEps":0,"open":241.75,"prevYearClose":159.39,"prevWeekClose":243.09,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":257.38,"twentyDayClose":268.39,"sixtyDayClose":265.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674899296","title":"集采围标案进入公诉阶段叠加FDA进口禁令，圣诺生物内外合规风险共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2674899296","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674899296?lang=zh_cn&edition=fundamental","pubTime":"2026-10-10 16:22","pubTimestamp":1791620558,"startTime":"0","endTime":"0","summary":"而就在9月下旬，该公司全资子公司被美国FDA列入进口禁令名单，对美业务全面“停摆”。案件由雨花台分局侦查终结后，以被告单位圣诺制药涉嫌串通投标罪于2026年1月向雨花台检察院移送起诉。圣诺生物已经启动了整改程序。公司公告援引FDA官网查询，圣诺制药于2026年9月19日被正式列入第66-40号进口禁令名单。圣诺生物在公告中承诺，解除FDA相关警示前，全面停止所有多肽原料药对美国市场的销售与发运。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1791620493545616840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","BK4588","LABU","688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674994278","title":"@澜沧人 2027年度城乡居民基本医疗保险今天可以开始缴费啦！","url":"https://stock-news.laohu8.com/highlight/detail?id=2674994278","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674994278?lang=zh_cn&edition=fundamental","pubTime":"2026-10-10 15:45","pubTimestamp":1791618300,"startTime":"0","endTime":"0","summary":"@澜沧人2027年度城乡居民医保于10月10日可以开始缴费啦！第二阶段：无财政补助，个人需全额缴费1124元。所以，大家一定记得及时缴费！","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-10-10/doc-iniutqmm7421927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","LABU","BK4581","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169663463","title":"异动解读｜三倍做多标普生物科技盘中上涨8.25%，生物科技板块杠杆ETF反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1169663463","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169663463?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 22:04","pubTimestamp":1791554695,"startTime":"0","endTime":"0","summary":"10月9日，三倍做多标普生物科技-Direxion盘中上涨8.25%，报240.94美元/股，成交额3734.08万美元。该ETF提供标普生物科技精选行业指数的三倍杠杆敞口，其涨幅显著放大同期标普生物科技精选行业指数的波动，反映杠杆效应下对生物科技板块反弹的放大作用。近期生物科技板块情绪波动持续加剧，此前美国利率预期变化对高久期、零收入型生物科技公司形成持续压制，投资者对加息担忧一度引发杠杆型生物科技产品深度回撤，而当前盘面显示超跌后的技术性修复动能增强。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"生物科技杠杆ETF反弹，超跌修复动能增强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674573598","title":"Alignment Healthcare股价跌至两年多以来的低点","url":"https://stock-news.laohu8.com/highlight/detail?id=2674573598","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674573598?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 21:38","pubTimestamp":1791553111,"startTime":"0","endTime":"0","summary":"Alignment Healthcare股价跌至两年多以来的低点","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610093891505231.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610093891505231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","ALHC","BK4588","XBI","XLV","BK4154","BK4581","BK4539","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674374548","title":"Alignment Healthcare股价盘前下跌23.2%，此前美国医疗保险和医疗补助服务中心公布了2027年联邦医","url":"https://stock-news.laohu8.com/highlight/detail?id=2674374548","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674374548?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 17:15","pubTimestamp":1791537353,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348723411.USD","ALHC","LU0256863811.USD","IEHS","UN","LU0390134368.USD","LU0320765489.SGD","BK4539","LU0208291251.USD","SG9999014021.USD","LU0238689110.USD","LU0417517546.SGD","LU0211331839.USD","UNHW","BK4533","BK4585","UNHU","LU1093756325.SGD","XBI","RSPH","BK4154","LU1983260115.SGD","XLV","SG9999014013.SGD","UNHG","HUM","LU0070302665.USD","LU0266013472.USD","BK4588","LU1093756168.USD","LABU","FXH","BK4581","IHF","BK4566","LU0170899867.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185813620","title":"医疗健康行业综述：市场观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1185813620","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185813620?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 16:22","pubTimestamp":1791534169,"startTime":"0","endTime":"0","summary":"医疗健康板块最新市场观察汇总。该股下跌2.0%，报2261.5日元。格林尼治时间12:08——摩根大通分析师援引近期与GSK首席执行官Luke Miels的通话称，Miels认为这家英国制药商的肿瘤业务被市场低估，并预计即将在医学大会上公布的最新进展将提振投资者信心。格林尼治时间11:25——瑞银分析师在一份报告中表示，Argenx决定停止其Vyvgart药物治疗干燥综合征的后期临床试验，对这家欧洲生物技术公司而言是一个重大的负面意外。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","LABU","BK4588","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141755341","title":"医疗保健综述：市场观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1141755341","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141755341?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 04:52","pubTimestamp":1791492761,"startTime":"0","endTime":"0","summary":"医疗保健板块最新市场观察。GSK首席执行官卢克·迈尔斯认为，这家英国制药公司的肿瘤业务被市场低估，并预计即将在医学大会上公布的更新将提振投资者信心，摩根大通分析师援引近期与迈尔斯的通话作出上述表示。摩根大通指出，GSK预计将在欧洲肿瘤内科学会年会上提供其肿瘤产品组合的最新进展，迈尔斯预期这将增强市场对其研发管线的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4585","BK4588","XBI","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674703002","title":"鲁宾制药获得美国FDA批准，可推出植物甲萘醌注射乳剂。","url":"https://stock-news.laohu8.com/highlight/detail?id=2674703002","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674703002?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 03:17","pubTimestamp":1791487074,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149502535","title":"医疗健康板块综述：市场观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1149502535","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149502535?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 00:26","pubTimestamp":1791476810,"startTime":"0","endTime":"0","summary":"医疗健康板块最新市场观察。分析师在一份报告中指出：“Miels重申了对GSK实现2031年销售额目标的信心，目标为超过400亿英镑，并强调产品组合的广度和深度，尤其是在肿瘤领域，他认为该领域被市场共识所低估。”摩根大通称，GSK预计将在欧洲肿瘤内科学会年度大会上提供其肿瘤产品组合的最新进展，Miels预计这将增强市场对其研发管线的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","XLV","BK4581","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126171378","title":"异动解读｜三倍做多标普生物科技盘中下跌8.24%，生物科技板块杠杆ETF承压明显","url":"https://stock-news.laohu8.com/highlight/detail?id=1126171378","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126171378?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 23:39","pubTimestamp":1791473943,"startTime":"0","endTime":"0","summary":"10月8日，三倍做多标普生物科技-Direxion盘中下跌8.24%，报209.175美元/股，成交额8120.05万美元。该ETF提供标普生物科技精选行业指数的三倍杠杆敞口，其跌幅显著放大同期标普生物科技精选行业指数的波动，反映杠杆效应下对生物科技板块回调的放大作用。近期生物科技板块情绪波动持续加剧，美国利率预期变化对高久期、零收入型生物科技公司形成持续压制，投资者对加息担忧重燃，导致杠杆型生物科技产品出现深度回撤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技杠杆ETF承压，疫苗数据引发板块重挫","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673032190","title":"美国健康保险公司股走弱，Humana跌3.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673032190","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673032190?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 22:12","pubTimestamp":1791468743,"startTime":"0","endTime":"0","summary":"美国健康保险公司股走弱，Humana跌3.2%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202610083889965661.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202610083889965661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LABU","XBI","BK4585","BK4588","BK4581","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673443008","title":"乐普医疗(300003.SZ)子公司MWN117注射液获得美国FDA药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2673443008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673443008?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 21:49","pubTimestamp":1791467386,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普医疗 发布公告，公司于今日获悉，公司控股子公司上海民为生物技术有限公司获得美国食品药品监督管理局关于同意MWN117注射液开展临床试验的通知书。MWN117注射液是上海民为生物自主研发的靶向抑制INHBE的siRNA药物，拥有全球知识产权，已于2026年8月获得CDE临床试验批准，适应症为超重或肥胖。同时，安全性评价试验显示MWN117注射液具有良好的安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","MDTX","BK0113","BK0196","IBBJ","300003","BK0251","BK4585","BK4588","BK0028","BK0201","IBBQ","LABU","BK0114","BK0188","PSYK","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673070279","title":"普门科技(688389.SH)：H100Plus血红蛋白检测系统获得美国FDA 510(k)准入","url":"https://stock-news.laohu8.com/highlight/detail?id=2673070279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673070279?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 21:21","pubTimestamp":1791465705,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普门科技(688389.SH)发布公告，近日，公司收到美国食品药品监督管理局(简称“FDA”)的通知，公司H100Plus血红蛋白检测系统获得美国FDA 510(k)准入。该产品用于体外定量检测人全血中糖化血红蛋白(HbA1c)的含量，可辅助糖尿病诊断。该产品获得美国FDA 510(k)准入，表明公司H100Plus血红蛋白检测系统符合FDA的相关要求，具备美国市场的准入资格，有利于进一步提升公司产品开拓海外市场的综合竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","688389","LABU","BK4588","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673319079","title":"普门科技：H100Plus血红蛋白检测系统获美国FDA准入","url":"https://stock-news.laohu8.com/highlight/detail?id=2673319079","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673319079?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 18:57","pubTimestamp":1791457049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673307989","title":"金达威(002626.SZ)子公司巴西甜蛋白产品获得美国FDA GRAS无异议函","url":"https://stock-news.laohu8.com/highlight/detail?id=2673307989","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673307989?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 18:52","pubTimestamp":1791456753,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金达威 发布公告，近日，公司全资子公司内蒙古金达威药业有限公司收到美国食品药品监督管理局出具的GRAS Notice No.GRN 001305 无异议回复函。金达威药业的巴西甜蛋白产品已完成FDA GRAS通告评估， FDA 对该产品申报用途下的GRAS结论出具无异议意见。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002626","BK0197","BK0077","159100","BK4588","BK4585","LABU","BK0226","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673507657","title":"乐普医疗：子公司MWN117获美国FDA批准开展I期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2673507657","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673507657?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 18:33","pubTimestamp":1791455610,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673078661","title":"ST人福(600079.SH)子公司盐酸地尔硫䓬片获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2673078661","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673078661?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 17:30","pubTimestamp":1791451819,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST人福(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”)近日收到美国食品药品监督管理局(FDA)关于盐酸地尔硫䓬片的批准文号。该药品主要用于治疗慢性稳定型心绞痛和冠状动脉痉挛引起的心绞痛。此次获批标志着宜昌人福具备了在美国市场销售该产品的资格，将对公司拓展美国仿制药市场带来积极的影响，宜昌人福后续将积极推进该产品在美国市场的上市准备工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600079","BK4585","BK0070","BK4588","BK0188","BK0028","BK0185","BK0012","LABU","BK0096","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673350020","title":"金达威：巴西甜蛋白获美国FDA GRN 001305无异议函","url":"https://stock-news.laohu8.com/highlight/detail?id=2673350020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673350020?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 17:01","pubTimestamp":1791450098,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673022492","title":"ST人福：盐酸地尔硫䓬片获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2673022492","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673022492?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 16:31","pubTimestamp":1791448272,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181612741","title":"医疗健康板块综述：市场观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1181612741","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181612741?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 16:22","pubTimestamp":1791447759,"startTime":"0","endTime":"0","summary":"医疗健康板块最新市场观察汇总。摩根大通认为，近期提振该集团业绩的监管利好已经结束，费森尤斯医疗可能面临营业利润萎缩。分析师称，阿斯利康股价近期承压，一些投资者正在争论其当前困境是否可与瑞士同行罗氏在2022至2025年间的遭遇相提并论，当时罗氏因一系列令人失望的试验而受到市场惩罚。伯恩斯坦将阿斯利康目标价从200便士下调至198便士。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","XLV","BK4588","BK4581","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}